Table 3.

Baseline demographics and medication for patients achieving remission after 3 and 6 months. Values are % or mean (95% CI) unless otherwise specified.

CharacteristicsRemission 3 MosRemission 6 Mos
DAS28CDAISDAIRAPID3ACR/EULAR BooleanACR/EULAR Boolean PracticeDAS28CDAISDAIRAPID3ACR/EULAR BooleanACR/EULAR Boolean Practice
No. patients, n (%)962 (22.5)494 (10.3)434 (9.8)979 (20.3)425 (8.7)510 (10.3)883 (26.0)478 (12.6)415 (11.8)817 (21.3)392 (10.1)477 (12.2)
Age, yrs54.8 (50.5–59.0)51.1 (49.8–52.4)51.7 (50.4–53.0)53.0 (50.8–55.3)51.5 (50.2–52.9)51.4 (50.6–53.1)52.9 (50.5–55.4)52.0 (50.7–53.4)52.3 (51.0–53.8)52.0 (50.6–52.6)51.4 (49.9–52.8)51.4 (50.1–52.8)
Females63.269.168.269.968.067.564.164.463.968.967.167.0
Disease duration, yrs6.7 (6.1–7.2)5.3 (4.6–6.0)5.4 (4.7–6.0)5.6 (5.1–6.1)5.5 (4.8–6.3)5.6 (4.9–6.3)6.3 (5.7–6.9)5.3 (4.6–6.0)5.3 (4.6–6.0)5.2 (4.7–5.7)5.7 (4.9–6.5)5.7 (5.0–6.4)
RF-positive68.168.368.767.767.868.362.966.765.864.965.366.8
Erosive disease46.040.642.946.843.144.645.143.643.045.544.145.0
High education41.944.044.344.845.444.642.543.243.744.845.544.0
Currently employed42.743.844.445.243.943.842.045.146.745.647.946.3
Current smoker23.722.222.422.622.922.822.420.720.524.820.721.6
Coffee > 4 cups daily25.523.224.221.823.523.325.123.523.924.922.322.5
DMARD use, last 4 weeks56.458.959.858.659.859.457.858.659.259.058.158.9
Current MTX monotherapy44.043.843.745.543.543.743.646.246.545.745.246.8
Current bDMARD29.532.732.027.732.031.428.733.133.526.832.731.9
  • DAS28: Disease Activity Score at 28 joints; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; RAPID3: Routine Assessment of Patient Index Data; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; ACR/EULAR Boolean: ACR/EULAR Boolean remission definition; ACR/EULAR Boolean Practice: ACR/EULAR Boolean remission definition for clinical practice; RF: rheumatoid factor; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; bDMARD: biological DMARD.